<i>PRAME, WT1</i> and <i>XIAP</i> tumor-associated genes expression in multiple myeloma patients
Tumor-associated genes (PRAME, WT1 and XIAP) expression study is conducted in 34 patients with multiple myeloma (MM) in disease onset and after chemotherapy (VAD, 20 pts) and proteosom inhibitor therapy (10 pts). PRAME, WT1 и XIAP gene expression in bone marrow cells detected by polymerase chain rea...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2022-11-01
|
| Series: | Онкогематология |
| Subjects: | |
| Online Access: | https://oncohematology.abvpress.ru/ongm/article/view/740 |
| _version_ | 1826557110778855424 |
|---|---|
| author | T. V. Gaponova L. P. Mendeleeva A. V. Misurin E. V. Varlamova V. G. Savchenko |
| author_facet | T. V. Gaponova L. P. Mendeleeva A. V. Misurin E. V. Varlamova V. G. Savchenko |
| author_sort | T. V. Gaponova |
| collection | DOAJ |
| description | Tumor-associated genes (PRAME, WT1 and XIAP) expression study is conducted in 34 patients with multiple myeloma (MM) in disease onset and after chemotherapy (VAD, 20 pts) and proteosom inhibitor therapy (10 pts). PRAME, WT1 и XIAP gene expression in bone marrow cells detected by polymerase chain reaction (PCR) method. PRAME gene expression in 62% primary patients was revealed, thus expression median was 0.3% that almost in 100 times greater than in bone marrow donors (0.0035%). WT1 gene expression in 20% patients was detected, and it was determined only in PRAMEpositive patients. At diagnosis XIAP gene expression was revealed in all MM patients, thus expression median was more 10 times greater than in the control groups (28% versus 2%). In patients with PRAME hyperexpression partial response was achieved only in 25% of cases, while in patients with low or absence of PRAME expression VAD therapy was effective in 75% of cases (р=0,06). After bortezomib treatment XIAP gene expression level was significantly decreased with complete and partial remission achievement: from 11-325% (median – 66%) to 1-123% (median – 20%). In cases of tumor resistance to bortezomib treatment XIAP expression increased from 16-127% (median – 36%) to 22-528% (median – 121%). |
| first_indexed | 2024-04-09T20:23:25Z |
| format | Article |
| id | doaj.art-b4bd167d75fa4494b5918642cabe9033 |
| institution | Directory Open Access Journal |
| issn | 1818-8346 2413-4023 |
| language | Russian |
| last_indexed | 2025-03-14T08:23:23Z |
| publishDate | 2022-11-01 |
| publisher | ABV-press |
| record_format | Article |
| series | Онкогематология |
| spelling | doaj.art-b4bd167d75fa4494b5918642cabe90332025-03-02T13:07:15ZrusABV-pressОнкогематология1818-83462413-40232022-11-0102525710.17650/1818-8346-2009-0-2-52-57618<i>PRAME, WT1</i> and <i>XIAP</i> tumor-associated genes expression in multiple myeloma patientsT. V. Gaponova0L. P. Mendeleeva1A. V. Misurin2E. V. Varlamova3V. G. Savchenko4Hematological Research Center, Russian Academy of Medical SciencesHematological Research Center, Russian Academy of Medical SciencesHematological Research Center, Russian Academy of Medical SciencesHematological Research Center, Russian Academy of Medical SciencesHematological Research Center, Russian Academy of Medical SciencesTumor-associated genes (PRAME, WT1 and XIAP) expression study is conducted in 34 patients with multiple myeloma (MM) in disease onset and after chemotherapy (VAD, 20 pts) and proteosom inhibitor therapy (10 pts). PRAME, WT1 и XIAP gene expression in bone marrow cells detected by polymerase chain reaction (PCR) method. PRAME gene expression in 62% primary patients was revealed, thus expression median was 0.3% that almost in 100 times greater than in bone marrow donors (0.0035%). WT1 gene expression in 20% patients was detected, and it was determined only in PRAMEpositive patients. At diagnosis XIAP gene expression was revealed in all MM patients, thus expression median was more 10 times greater than in the control groups (28% versus 2%). In patients with PRAME hyperexpression partial response was achieved only in 25% of cases, while in patients with low or absence of PRAME expression VAD therapy was effective in 75% of cases (р=0,06). After bortezomib treatment XIAP gene expression level was significantly decreased with complete and partial remission achievement: from 11-325% (median – 66%) to 1-123% (median – 20%). In cases of tumor resistance to bortezomib treatment XIAP expression increased from 16-127% (median – 36%) to 22-528% (median – 121%).https://oncohematology.abvpress.ru/ongm/article/view/740multiple myelomatumor-associated genes <i>pramewt1xiap</i>chemotherapyproteosom inhibitorsbortezomib |
| spellingShingle | T. V. Gaponova L. P. Mendeleeva A. V. Misurin E. V. Varlamova V. G. Savchenko <i>PRAME, WT1</i> and <i>XIAP</i> tumor-associated genes expression in multiple myeloma patients Онкогематология multiple myeloma tumor-associated genes <i>prame wt1 xiap</i> chemotherapy proteosom inhibitors bortezomib |
| title | <i>PRAME, WT1</i> and <i>XIAP</i> tumor-associated genes expression in multiple myeloma patients |
| title_full | <i>PRAME, WT1</i> and <i>XIAP</i> tumor-associated genes expression in multiple myeloma patients |
| title_fullStr | <i>PRAME, WT1</i> and <i>XIAP</i> tumor-associated genes expression in multiple myeloma patients |
| title_full_unstemmed | <i>PRAME, WT1</i> and <i>XIAP</i> tumor-associated genes expression in multiple myeloma patients |
| title_short | <i>PRAME, WT1</i> and <i>XIAP</i> tumor-associated genes expression in multiple myeloma patients |
| title_sort | i prame wt1 i and i xiap i tumor associated genes expression in multiple myeloma patients |
| topic | multiple myeloma tumor-associated genes <i>prame wt1 xiap</i> chemotherapy proteosom inhibitors bortezomib |
| url | https://oncohematology.abvpress.ru/ongm/article/view/740 |
| work_keys_str_mv | AT tvgaponova ipramewt1iandixiapitumorassociatedgenesexpressioninmultiplemyelomapatients AT lpmendeleeva ipramewt1iandixiapitumorassociatedgenesexpressioninmultiplemyelomapatients AT avmisurin ipramewt1iandixiapitumorassociatedgenesexpressioninmultiplemyelomapatients AT evvarlamova ipramewt1iandixiapitumorassociatedgenesexpressioninmultiplemyelomapatients AT vgsavchenko ipramewt1iandixiapitumorassociatedgenesexpressioninmultiplemyelomapatients |